Careers  |  Sign In  |  Register

Minimal Residual Disease in Hematologic Malignancies: Testing Considerations and Challenges

In this webcast symposium, Gail J. Roboz, MD, professor of medicine and director of the Clinical and Translational Leukemia Program at the Weill Medical College of Cornell University and the New York-Presbyterian Hospital in New York City, discusses the role of minimal residual disease testing in the treatment of patients with acute myeloid leukemia (AML). Dr. Roboz shares patient cases and data from recent clinical trials in this comprehensive presentation.


Brian A. Jonas, MD, PhD, FACP
Brian A. Jonas, MD, PhD, FACP

Associate Professor of Medicine

Chair, Hematologic Malignancies Disease Team Committee

Division of Hematology and Oncology

University of California Davis School of Medicine

Sacramento, CA

Gabriel N. Mannis, MD
Gabriel N. Mannis, MD

Assistant Professor of Medicine

Division of Hematology

Stanford Cancer Institute

Stanford University

Stanford, CA